BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF BIOSTAR PHARMACEUTICALS, INC. This is to certify that: FIRST SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Inc. Ronghua Wang Shuang Gong Chief Executive Officer Secretary EX-3.1 2 ex3-1.htm] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCK SPLIT -- XIANYANG, China, April 3, 2012 As a result of the reverse stock split, the number of outstanding common shares will be reduced to approximately 9,398,892. Fractional stockholdings will be rounded up to the nearest whole number. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder’s ownership]

By | 2016-03-03T12:06:04+00:00 April 4th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION

[ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF BIOSTAR PHARMACEUTICALS, INC. This is to certify that: FIRST SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Inc. Ronghua Wang Shuang Gong Chief Executive Officer Secretary EX-3.1 2 ex3-1.htm] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCK SPLIT -- XIANYANG, China, April 3, 2012 As a result of the reverse stock split, the number of outstanding common shares will be reduced to approximately 9,398,892. Fractional stockholdings will be rounded up to the nearest whole number. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder’s ownership]

By | 2016-03-03T12:08:17+00:00 April 4th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[ARTICLES OF AMENDMENT TO THE ARTICLES OFORPORATION OF BIOSTAR PHARMACEUTICALS, This is to certify that: SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Ronghua Wang Shuang Gong Chief Executive Officer Secretary ex3-1.htm 2 EX-3.1] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCKLIT -- XIANYANG, China, April 3, 2012 a result of the reverse stocklit, the number of outstandingmmon shares will be reduced to approximately 9,398,892.Fractional stockholdings will be rounded up to the nearest whole number.The reverse stocklit will affectl stockholders uniformly and will not affect any stockholders ownership percentage of the]

By | 2016-02-07T15:52:17+00:00 April 4th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: ARTICLES OF AMENDMENT TO THE ARTICLES OFORPORATION OF

[ARTICLES OF AMENDMENT TO THE ARTICLES OFORPORATION OF BIOSTAR PHARMACEUTICALS, This is to certify that: SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Ronghua Wang Shuang Gong Chief Executive Officer Secretary ex3-1.htm 2 EX-3.1] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCKLIT -- XIANYANG, China, April 3, 2012 a result of the reverse stocklit, the number of outstandingmmon shares will be reduced to approximately 9,398,892.Fractional stockholdings will be rounded up to the nearest whole number.The reverse stocklit will affectl stockholders uniformly and will not affect any stockholders ownership percentage of the]

By | 2016-02-07T15:53:10+00:00 April 4th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL] DEF 14A: (Original Filing)

[Skystar Bio-Pharmaceuticalmpany Notice of Annual Meeting and Proxy Statement Annual Meeting to be held on April 27, 2012, at 4/F Building B Chuangye Square, No. 48 Keji Road, Gaoxin District, Xian, Shaanxi Province, P.R. China, at 7:45pm, local timeystar Bio-Pharmaceuticalmpany 4/F Building B Chuangye Square, No. 48 Keji Road,]

By | 2016-02-05T03:18:48+00:00 April 3rd, 2012|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL] DEF 14A: Skystar Bio-Pharmaceuticalmpany Notice of Annual Meeting and Proxy

[Skystar Bio-Pharmaceuticalmpany Notice of Annual Meeting and Proxy Statement Annual Meeting to be held on April 27, 2012, at 4/F Building B Chuangye Square, No. 48 Keji Road, Gaoxin District, Xian, Shaanxi Province, P.R. China, at 7:45pm, local timeystar Bio-Pharmaceuticalmpany 4/F Building B Chuangye Square, No. 48 Keji Road,]

By | 2016-02-05T03:19:57+00:00 April 3rd, 2012|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-K: (Original Filing)

[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer March 30, 2012] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Bing Mei Chief Financial Officer March 30, 2012]

By | 2016-03-01T04:51:35+00:00 March 30th, 2012|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-K:

[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer March 30, 2012] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Bing Mei Chief Financial Officer March 30, 2012]

By | 2016-03-01T04:52:13+00:00 March 30th, 2012|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Read More
Skip to toolbar